We previously reported the discovery of a bispecific antibody, termed V2, which can specifically bind to the KRASG12V-HLA-A*03:01 neoantigen and drive T-cell-mediated killing of KRASG12V-containing cancer cells without non-specific activity against wild-type KRAS or other codon 12 mutations19. This evidence concerns the gene KRAS and cancer.